DIA
Drug Information Association Logo
« Back to Listing

Health Care's Revolutionary Printing Press? 3D Printing - Blue Sky and Regulatory Path

Track:
Public Policy/Health Care Compliance/Law

Day & Time:
June 17, 10:30AM - 12:00PM (Pacific Standard Time)

Session Number:
242

Room Number:
6E

Level:
Intermediate

Type:
Forum

Title:
Health Care's Revolutionary Printing Press? 3D Printing - Blue Sky and Regulatory Path

Chair(s):
Nancy Bradish Myers, JD
President
Catalyst Healthcare Consulting, Inc, United States

Description:
Disruptive technology and health care are not usually used in the same sentence. We don't hear "Let's print out a new drug" or "How about a new ear" every day either. While news articles have only speculated about how 3D printing could revolutionize drug discovery and tissue regeneration, the technology is already being used in certain areas of health care - for example, to create customized joint replacements. Come hear experts from the 3D printing world, regulatory officials, and industry leaders discuss the potential impact of 3D printing on drug discovery and health delivery, and the regulatory challenges the technology may face as it continues its advance into health care.

Learning Objective(s):
Identify the ways in which 3D printing could change medical product development; Define the regulatory challenges associated with 3D printing, and potential approaches by regulators; Identify ways in which 3D printing may impact your organization.

Presentation(s) & Speaker(s):
Scientific Policy on 3D Printers
Steven K. Pollack
Director, Office of Science and Engineering Labs, CDRH
FDA , United States

Industry Perspective
Eric M. David, JD, MD
Co-Founder and Chief Strategy Officer
Organovo, Inc., United States

Industry Perspective
Brian M. Strem
Director, Business Development
Allergan, Inc., United States